Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in Infancy
Clinical Infectious Diseases2010Vol. 51(2), pp. 185–188
Citations Over TimeTop 10% of 2010 papers
Abstract
Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.
Related Papers
- → A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV(2016)18 cited
- → Paramyxoviruses: Respiratory Syncytial Virus and Human Metapneumovirus(2014)13 cited
- → Potential for Palivizumab Interference With Commercially Available Antibody–antigen Based Respiratory Syncytial Virus Diagnostic Assays(2013)8 cited
- → Pneumoviruses: Respiratory Syncytial Virus and Human Metapneumovirus(2022)3 cited
- → Vaccine against respiratory syncytial virus is recombinant vaccinia virus, especially vaccinia RSV G and F glycoprotein virus(1987)